Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/38003
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorSánchez Caraballo, Jorge Mario-
dc.contributor.authorGarcía Gómez, Elizabeth-
dc.contributor.authorChapman, Edgardo-
dc.contributor.authorGarcía Paba, María Beatriz-
dc.contributor.authorOcampo Gómez, Jaime-
dc.contributor.authorEgea Bermejo, Eduardo-
dc.contributor.authorGaravito De Egea, Gloria-
dc.contributor.authorFang, Luis-
dc.contributor.authorSarrazola, Mauricio-
dc.contributor.authorSerrano Reyes, Carlos-
dc.contributor.authorSilva Espinosa, Diana Lucia-
dc.contributor.authorRojas Mejía, Dolly Vanessa-
dc.contributor.authorMoreno López, Sergio Mauricio-
dc.date.accessioned2024-02-04T00:10:46Z-
dc.date.available2024-02-04T00:10:46Z-
dc.date.issued2022-
dc.identifier.citationGarcía-Gómez E, Chapman E, García-Paba MB, Ocampo-Gómez J, Egea-Bermejo E, Garavito-De Egea G, Fang L, Sarrazola M, Sánchez-Caraballo JM, Serrano-Reyes C, Silva-Espinosa DL, Rojas-Mejía DV, Moreno SM. Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia. Front Allergy. 2022 May 20;3:902344. doi: 10.3389/falgy.2022.902344. PMID: 35769574; PMCID: PMC9234875.spa
dc.identifier.issn2673-6101-
dc.identifier.urihttps://hdl.handle.net/10495/38003-
dc.description.abstractABSTRACT: Although chronic urticaria (CU) is a common, cause of medical consulting both in general practitioners and allergist specialists worldwide, there is little information about its behavior and management in Latin America. Currently, national and international guidelines recommend using Omalizumab for cases refractory to management with antihistamines. Despite advances in the knowledge of Omalizumab for the management of CU, although there are few studies in underdeveloped countries, there are many studies evaluating the impact of Omalizumab treatment. There is not clinical information related with CSU-Omalizumab in patient settled in the Caribbean area. This research aims to evaluate the management of CU with Omalizumab in a real-life scenario in Colombia.spa
dc.format.extent8spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherFrontiers Mediaspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleMulticentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombiaspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Alergología Clínica y Experimental (GACE)spa
dc.identifier.doi10.3389/falgy.2022.902344-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn2673-6101-
oaire.citationtitleFrontiers in Allergyspa
oaire.citationstartpage1spa
oaire.citationendpage8spa
oaire.citationvolume3spa
oaire.citationissue902344spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeLausana, Suizaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsUrticaria-
dc.subject.decsAngioedema-
dc.subject.decsAntagonistas de los Receptores Histamínicos-
dc.subject.decsHistamine Antagonists-
dc.subject.decsOmalizumab-
dc.subject.lembAntihistamínicos-
dc.subject.lembAntihistamines-
dc.description.researchgroupidCOL0059567spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D014581-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000799-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006633-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000069444-
dc.relation.ispartofjournalabbrevFront. Allergy.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
SanchezJorge_2022_OmalizumabInducibleAntihistamines.pdfArtículo de investigación453.32 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons